Skip to main content
SpringerLink
Log in

COPD

Roflumilast on top reduziert Exazerbationen

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Tashkin DP. Dual anti-inflammatory agents prevent COPD exacerbations. Lancet 2015;385(9971):832–4.

    Article  PubMed  Google Scholar 

Literatur

  • Martinez FJ, Calverley PM, Goehring UM et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857–66.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Klinische Pharmakologie, Universitätsklinikum Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Deutschland

    Klaus Mörike

Authors
  1. Klaus Mörike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mörike.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mörike, K. Roflumilast on top reduziert Exazerbationen. Pneumo News 7, 31 (2015). https://doi.org/10.1007/s15033-015-0143-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0143-6

Search

Navigation